These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7878647)

  • 1. Influence of lupus anticoagulant on a commercially available kit for APC-resistance.
    Halbmayer WM; Haushofer A; Schön R; Fischer M
    Thromb Haemost; 1994 Oct; 72(4):645-6. PubMed ID: 7878647
    [No Abstract]   [Full Text] [Related]  

  • 2. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
    Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV
    Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. The APC Resistance Study Group.
    Rosén S; Johansson K; Lindberg K; Dahlbäck B
    Thromb Haemost; 1994 Aug; 72(2):255-60. PubMed ID: 7831662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance assay as a screening test for thromboembolic disposition.
    Shizuka R; Amagai H; Kojima J; Fukumura Y; Kanda T; Kobayashi I
    J Med; 1997; 28(5-6):381-6. PubMed ID: 9604796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
    Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
    Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the mechanism of thrombosis by lupus anticoagulant inhibited protein C pathway].
    Wu J; Zhou Z; Xu J
    Zhonghua Xue Ye Xue Za Zhi; 2001 Sep; 22(9):470-2. PubMed ID: 11758227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.
    Bertina RM; Reitsma PH; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1995 Jul; 74(1):449-53. PubMed ID: 8578504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene.
    Bokarewa MI; Bremme K; Falk G; Sten-Linder M; Egberg N; Blombäck M
    Thromb Res; 1995 May; 78(3):193-200. PubMed ID: 7631299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S.
    Denson KW; Haddon ME; Reed SV; Davidson S; Littlewood TJ
    Thromb Res; 1996 Jan; 81(1):151-6. PubMed ID: 8747530
    [No Abstract]   [Full Text] [Related]  

  • 11. [Lupus anticoagulant as a risk factor of thrombosis].
    Lewandowski K; Zawilska K
    Pol Tyg Lek; 1992 Feb 3-10; 47(5-6):154-5. PubMed ID: 1437806
    [No Abstract]   [Full Text] [Related]  

  • 12. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract.
    Martorell JR; Muñoz-Castillo A; Gil JL
    Thromb Haemost; 1995 Aug; 74(2):796-7. PubMed ID: 8585026
    [No Abstract]   [Full Text] [Related]  

  • 13. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.
    Galli M; Dlott J; Norbis F; Ruggeri L; Cler L; Triplett DA; Barbui T
    Thromb Haemost; 2000 Dec; 84(6):1012-6. PubMed ID: 11154107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired activated protein C-resistance in patients with lupus anticoagulants.
    Ehrenforth S; Radtke KP; Scharrer I
    Thromb Haemost; 1995 Aug; 74(2):797-8. PubMed ID: 8585027
    [No Abstract]   [Full Text] [Related]  

  • 15. A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with a lupus anticoagulant.
    Benattar N; Schved JF; Biron-Andréani C
    Thromb Haemost; 2000 Jun; 83(6):967-8. PubMed ID: 10896260
    [No Abstract]   [Full Text] [Related]  

  • 16. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
    Moore GW; Rangarajan S; Savidge GF
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Activated protein C resistance as a cause of thrombophilia].
    Ruiz-Argüelles GJ
    Rev Invest Clin; 1996; 48(3):223-9. PubMed ID: 8966383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rebuttal to: strong lupus anticoagulant can influence the prothrombin time INR falsifying the follow up of oral anticoagulation.
    Bailleul E; Van Vaerenbergh K; Lust A
    Thromb Haemost; 2005 Sep; 94(3):687; author reply 688. PubMed ID: 16268495
    [No Abstract]   [Full Text] [Related]  

  • 19. Activated protein C resistance: molecular mechanisms.
    Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
    de Laat B; Eckmann CM; van Schagen M; Meijer AB; Mertens K; van Mourik JA
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):757-64. PubMed ID: 19002041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.